HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

N1- hydroxy- N8- (4- (phenylamino)phenyl)octanediamide

structure in first source

Also Known As:

MHY219

Networked: 2 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amines: 4871
  - Aniline Compounds: 46
    - Diphenylamine: 109
      - N1-hydroxy-N8-(4-(phenylamino)phenyl)octanediamide: 2
  - Hydroxylamines: 16
    - Hydroxamic Acids: 239
      - N1-hydroxy-N8-(4-(phenylamino)phenyl)octanediamide: 2
- Carboxylic Acids: 973
  - Hydroxy Acids: 94
    - Hydroxamic Acids: 239
      - N1-hydroxy-N8-(4-(phenylamino)phenyl)octanediamide: 2

Experts

1.	Ahn, Mee Young: 2 articles (09/2015 - 06/2013)
2.	De, Umasankar: 2 articles (09/2015 - 06/2013)
3.	Kim, Hyung Sik: 2 articles (09/2015 - 06/2013)
4.	Lee, Byung Mu: 2 articles (09/2015 - 06/2013)
5.	Patra, Nabanita: 2 articles (09/2015 - 06/2013)
6.	Yoon, Jung Hyun: 2 articles (09/2015 - 06/2013)
7.	Ahn, Ji Hae: 1 article (09/2015)
8.	Kundu, Soma: 1 article (09/2015)
9.	Moon, Hyung Ryoung: 1 article (09/2015)
10.	Son, Ji Yeon: 1 article (09/2015)

Related Diseases

1.	Prostatic Neoplasms (Prostate Cancer) 09/01/2015 - "In the present study, we evaluated MHY219 molecular mechanisms involved in the regulation of prostate cancer cell migration. " 09/01/2015 - "We previously investigated MHY219, a new HDAC inhibitor, and its potent anticancer activity in human prostate cancer cells. " 09/01/2015 - "A New Histone Deacetylase Inhibitor, MHY219, Inhibits the Migration of Human Prostate Cancer Cells via HDAC1." 06/01/2013 - "MHY219 increased histone H3 hyperacetylation and reduced the expression of class I HDACs (1, 2 and 3) in prostate cancer cells. " 06/01/2013 - "These results indicate that MHY219 is a potent HDAC inhibitor that targets regulating multiple aspects of cancer cell death and might have preclinical value in human prostate cancer chemotherapy, warranting further investigation."
2.	Neoplasms (Cancer) 09/01/2015 - "These results suggest that MHY219 may potentially be used as an anticancer agent to block cancer cell migration through the repression of MMP-1 and MMP-2, which is related to the reduction of HDAC1. " 06/01/2013 - "These results indicate that MHY219 is a potent HDAC inhibitor that targets regulating multiple aspects of cancer cell death and might have preclinical value in human prostate cancer chemotherapy, warranting further investigation."

Related Drugs and Biologics

1.	Histone Deacetylase Inhibitors
2.	Histones (Histone)
3.	Histone Deacetylases (Histone Deacetylase)
4.	Antineoplastic Agents (Antineoplastics)
5.	Vorinostat

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)